Citigroup
TEVA icon

Citigroup’s Teva Pharmaceuticals TEVA Stock Holding History

Citigroup’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-112,500
Closed -$3.51M – 6393
2025
Q4 		$3.51M Buy
112,500
+50,000
+80% +$1.23M ﹤0.01% 2270
2025
Q3 		$1.26M Buy
+62,500
New +$1.1M ﹤0.01% 3014
2025
Q2 		– Sell
-6,072,000
Closed -$93.3M – 5899
2025
Q1 		$93.3M Buy
6,072,000
+6,027,000
+13,393% +$108M 0.05% 339
2024
Q4 		$992K Hold
45,000
– – ﹤0.01% 3375
2024
Q3 		$811K Hold
45,000
– – ﹤0.01% 3426
2024
Q2 		$731K Sell
45,000
-6,180,000
-99% -$95.2M ﹤0.01% 3126
2024
Q1 		$87.8M Buy
+6,225,000
New +$78.5M 0.06% 307
2023
Q3 		– Sell
-200,000
Closed -$1.51M – 5802
2023
Q2 		$1.51M Sell
200,000
-9,316,200
-98% -$75.5M ﹤0.01% 2489
2023
Q1 		$84.2M Buy
9,516,200
+6,568,900
+223% +$65M 0.06% 253
2022
Q4 		$26.9M Sell
2,947,300
-1,500,000
-34% -$13.1M 0.02% 659
2022
Q3 		$35.9M Sell
4,447,300
-3,883,200
-47% -$34.3M 0.03% 508
2022
Q2 		$62.6M Sell
8,330,500
-1,064,900
-11% -$9.28M 0.05% 324
2022
Q1 		$88.2M Sell
9,395,400
-435,100
-4% -$3.63M 0.05% 310
2021
Q4 		$78.7M Buy
9,830,500
+9,330,500
+1,866% +$84.2M 0.04% 394
2021
Q3 		$4.87M Sell
500,000
-450,000
-47% -$4.21M ﹤0.01% 1846
2021
Q2 		$9.4M Buy
950,000
+450,000
+90% +$4.76M 0.01% 1467
2021
Q1 		$5.77M Sell
500,000
-1,503,700
-75% -$17.2M ﹤0.01% 1691
2020
Q4 		$19.3M Sell
2,003,700
-165,100
-8% -$1.58M 0.01% 1059
2020
Q3 		$19.5M Sell
2,168,800
-136,800
-6% -$1.45M 0.01% 911
2020
Q2 		$28.4M Sell
2,305,600
-3,131,400
-58% -$35.4M 0.02% 633
2020
Q1 		$48.8M Buy
5,437,000
+1,573,800
+41% +$16.1M 0.04% 368
2019
Q4 		$37.9M Buy
3,863,200
+1,727,900
+81% +$15.4M 0.03% 629
2019
Q3 		$14.7M Buy
2,135,300
+501,900
+31% +$3.85M 0.01% 1124
2019
Q2 		$15.1M Buy
1,633,400
+501,100
+44% +$6.04M 0.01% 1107
2019
Q1 		$17.8M Sell
1,132,300
-2,784,500
-71% -$49.1M 0.02% 902
2018
Q4 		$60.4M Buy
3,916,800
+2,414,000
+161% +$49.5M 0.06% 329
2018
Q3 		$32.4M Sell
1,502,800
-97,900
-6% -$2.27M 0.03% 577
2018
Q2 		$38.9M Sell
1,600,700
-184,700
-10% -$3.77M 0.04% 452
2018
Q1 		$30.5M Sell
1,785,400
-237,300
-12% -$4.63M 0.03% 577
2017
Q4 		$38.3M Buy
2,022,700
+50,600
+3% +$761K 0.03% 533
2017
Q3 		$34.7M Buy
1,972,100
+664,800
+51% +$15M 0.03% 534
2017
Q2 		$43.4M Buy
1,307,300
+89,600
+7% +$2.77M 0.04% 409
2017
Q1 		$39.1M Buy
1,217,700
+208,100
+21% +$7.1M 0.03% 461
2016
Q4 		$36.6M Sell
1,009,600
-234,600
-19% -$9.37M 0.03% 486
2016
Q3 		$57.2M Buy
1,244,200
+413,500
+50% +$21.6M 0.05% 310
2016
Q2 		$41.7M Buy
830,700
+329,100
+66% +$17.5M 0.04% 370
2016
Q1 		$26.8M Sell
501,600
-6,000
-1% -$352K 0.03% 496
2015
Q4 		$33.3M Sell
507,600
-171,800
-25% -$10.6M 0.03% 500
2015
Q3 		$38.4M Buy
679,400
+147,500
+28% +$9.56M 0.04% 432
2015
Q2 		$31.4M Buy
531,900
+99,200
+23% +$6.12M 0.03% 560
2015
Q1 		$27M Sell
432,700
-70,100
-14% -$4.08M 0.03% 619
2014
Q4 		$28.9M Buy
502,800
+39,900
+9% +$2.22M 0.03% 623
2014
Q3 		$24.9M Sell
462,900
-85,100
-16% -$4.51M 0.02% 685
2014
Q2 		$28.7M Sell
548,000
-174,200
-24% -$8.9M 0.03% 583
2014
Q1 		$38.2M Sell
722,200
-930,400
-56% -$43M 0.04% 421
2013
Q4 		$66.2M Buy
1,652,600
+1,215,800
+278% +$47.9M 0.06% 292
2013
Q3 		$16.5M Buy
436,800
+120,200
+38% +$4.69M 0.02% 838
2013
Q2 		$12.4M Buy
+316,600
New +$12.3M 0.01% 939

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's TEVA Position: Q1 2026 in Review

Citigroup reduced its Teva Pharmaceuticals (TEVA) stake by 38% in Q1 2026, selling an estimated $16.4M and leaving 832,323 shares worth $25.1M. The position accounts for 0.01% of the portfolio, ranked #953.

Citigroup first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $135M in Q2 2018. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Citigroup held 832,323 shares of Teva Pharmaceuticals worth $25.1M as of Q1 2026.
  • Citigroup sold 511,168 Teva Pharmaceuticals shares in Q1 2026, an estimated $16.4M.
  • Teva Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #953 holding.
  • Citigroup first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Teva Pharmaceuticals position peaked at $135M in Q2 2018.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.